Atreca Inc at Canaccord Genuity Growth Conference Transcript
Good afternoon, everyone. Thank you for joining us for the 42nd annual Canaccord Genuity growth conference. I'm John Newman. I'm one of the Biotech Analysts here at Canaccord. We're very excited to have Atreca with us today, represented by Mr. Tito Serafini, as well as Dr. Jonathan Benjamin. So gentlemen, welcome.
I wondered if we could start by just having you describe the technology developed by Atreca to identify targets and how it's unique in the sector. And to the audience, this might sound like kind of a generic question, but the way that this company has developed technology to identify targets is very, very different from everybody else. So I just wonder if you could tell us a bit about that.
Sure. First, thanks very much for inviting us here today. So first, I think, it's the approach that's unique and the unique technology that enables us to execute on that approach. So, we look for new targets, novel targets, and novel epitopes of existing targets
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |